title: [Neonatal localized neuroblastoma: 52 cases treated from 1990 to 1999].
abstract: Neuroblastoma is the most frequent tumor observed in the newborn. The aim of this study was to review clinical features, treatment and outcome of newborns diagnosed with a localized neuroblastoma.
  
  
  METHODS
  Data from 52 cases treated according to the NBL 90 and 94 protocols between 1990 and 1999 in 18 French centers of pediatric oncology were analyzed.
  
  
  RESULTS
  The median age at diagnosis was 12 days (range 0-28) with antenatal detection in 14 patients (27%). Tumor location was abdominal in 40 patients (adrenal in 20 of the 40), thoracic in eight, pelvic in three, and cervical in one. N-myc amplification was observed in one out of 40 evaluable cases. The size of the primary tumor was less than 5 cm in 25 cases, between 5 and 10 cm in 25 and more than 10 cm in two. Dumbbell tumor was observed in seven, of whom five had neurological deficit. One child died from hemorrhage after fine needle biopsy during diagnostic procedure. Primary surgical resection was attempted in 37 infants, of whom two died of surgery related complications and three had nephrectomy. Tumor was deemed as unresectable in 14 patients, and primary chemotherapy was given followed by surgical excision in 12. One of them died a few days after the beginning of chemotherapy. As a whole, continuous complete remission was achieved in 48 children, four of them after relapse. Overall survival was 92% with a median follow-up of 46 months (0-113 months).
  
  
  CONCLUSIONS
  The excellent prognosis of localized NB in neonates needs very restrictive surgical indications, with well-established anatomic and imaging criteria. Indeed, chemotherapy based on weight and managed by expert teams should allow to perform surgical excision in safer conditions for unresectable tumors.
authors.affiliation: Département de pédiatrie, hôpital Michallon, BP 217X, 38045 Grenoble, France.
authors.forename: M B
authors.initials: MB
authors.lastname: Michalowski
authors.forename: H
authors.initials: H
authors.lastname: Rubie
authors.forename: J
authors.initials: J
authors.lastname: Michon
authors.forename: S
authors.initials: S
authors.lastname: Montamat
authors.forename: C
authors.initials: C
authors.lastname: Bergeron
authors.forename: C
authors.initials: C
authors.lastname: Coze
authors.forename: Y
authors.initials: Y
authors.lastname: Perel
authors.forename: D
authors.initials: D
authors.lastname: Valteau-Couanet
authors.forename: J
authors.initials: J
authors.lastname: Guitard
authors.forename: J M
authors.initials: JM
authors.lastname: Guys
authors.forename: C
authors.initials: C
authors.lastname: Piolat
authors.forename: C
authors.initials: C
authors.lastname: Munzer
authors.forename: D
authors.initials: D
authors.lastname: Plantaz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome